期刊文献+

Ras/Raf/MEK/ERK通路在食管癌药物靶向治疗中的作用 被引量:10

Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma
原文传递
导出
摘要 Ras蛋白是调节细胞生长、增殖和分化的重要元件。当Ras变异时,可引起细胞的异常增殖,导致肿瘤的发生。胞外信号调控激酶(ERK)是Ras下游效应子,在恶性肿瘤细胞的生长和预后中扮演重要角色。近来研究证明,在Ras和ERK之间还存在其他相关的效应子,相互之间构成了一条完整的Ras/Raf/MEK/ERK信号通路,在食管肿瘤的发病过程中起着重要作用,部分针对该通路的抗肿瘤药物已在临床中应用。对于Ras/Raf/MEK/ERK信号通路中分子机制的进一步理解,可为制定更有效的食管肿瘤靶向治疗方法创造条件。本文就该信号通路在食管癌中的作用及药物靶点做一综述。 Ras is best known for its ability to regulate cell growth, proliferation and differentiation. Mutations in Ras are associated with the abnormal cell proliferation which can result in incidence of all human cancers. Extracellular signal-regulated kinase (ERK) is a downstream effector of Ras and plays important roles in prognosis of tumors. Recently, evidence has gradually accumulated to demonstrate that there are other effectors between Ras and ERK, these proteins interact each other and constitute the thorough Ras/Raf/MEK/ ERK signaling pathway. The pathway has profound effects on incidence of esophageal carcinoma and clinical applications of some chemotherapeutic drugs targeting the pathway. Further understanding of the relevant molecular mechanisms of Ras/Raf/MEK/ERK signaling pathway can be helpful for the development of efficient targeting therapeutic approaches which contribute to the treatment of esophageal cancer. In this article, roles of Ras/Raf/MEK/ERK signaling pathway in esophageal carcinoma as well as pharmacological targeting point in the pathway are reviewed.
出处 《药学学报》 CAS CSCD 北大核心 2013年第5期635-641,共7页 Acta Pharmaceutica Sinica
关键词 食管癌 信号通路 靶向治疗 esophageal cancer signaling pathway targeting therapy
  • 相关文献

参考文献5

二级参考文献76

  • 1王益民,郭炜,张秀凤,李琰,王娜,葛晖,魏丽珍,温登瑰,张健慧.丝氨酸羟甲基转移酶基因C1420T多态性与食管鳞癌、贲门腺癌易感性的关系[J].癌症,2006,25(3):281-286. 被引量:9
  • 2张立明,郑传莉.氧化苦参碱诱导骨肉瘤细胞凋亡的实验研究[J].中国医院药学杂志,2006,26(10):1218-1220. 被引量:8
  • 3Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor [J]. Cardiovasc Drug Rev, 2002, 20: 303-328.
  • 4Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts [J]. Drug Discov Today, 2007, 12: 34-42.
  • 5Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands [J]. Drug Discov Today, 2004, 9: 641-651.
  • 6Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study [J]. JAMA, 2000, 284: 1247-1255.
  • 7Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial [J]. JAMA, 2000, 5, 283: 1695-1702.
  • 8Gore M, Carmichael J, Gordon A, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer [J]. J Clin Oncol, 1997, 15: 2183-2193.
  • 9Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy [J]. Trends Mol Med, 2002, 8(4 Suppl): S14-18.
  • 10Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and an giogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J]. Clin Cancer Res, 2001, 7: 1459.

共引文献55

同被引文献99

引证文献10

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部